Abstract
Forty-four adult BMT recipients transplanted from an HLA-identical sibling donor were randomized to receive meningococcal polysaccharide (Men PS) vaccine either 8 (early group; 22 patients) or 20 (late group; 22 patients) months after BMT. The geometric mean concentrations (GMC) of antibodies to serogroup A Neisseria meningitidis (Men A) and serogroup C Neisseria meningitidis (Men C), determined by an EIA method, decreased during the first 6 months after BMT but remained at a stable level thereafter. Before vaccination the GMCs of anti-Men A were 1.53 μg/ml and 1.61 μg/ml, but 1 month after vaccination they were significantly higher, 3.46 μg/ml and 6.39 μg/ml, in the early and late groups. The GMCs of anti-Men C increased from 0.37 μg/ml and 0.44 μg/ml before vaccination to 3.31 μg/ml and 4.62 μg/ml at 1 month after vaccination in the early and late groups, respectively. By 6 months after vaccination the GMCs of Men antibodies had decreased to levels of about 50% of those measured at 1 month after vaccination. Two-fold responses to Men A PS were seen in 52% and 74% and to Men C PS in 76% and 89% of the BMT recipients in the early and late groups, respectively. Chronic GVHD had no influence on the vaccination response. In the present study, Men PS vaccine induced good and equal antibody responses to Men A and Men C PSs in allogeneic BMT recipients regardless of timing after BMT. Vaccination against Neisseria meningitidis should be considered, especially in the event of travelling or military service ⩾8 months after BMT. Bone Marrow Transplantation (2001) 27, 79–84.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jafari HS, Perkins BA . Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 1997 46: 1–10
Ramsay M, Kaczmarski E, Rush M et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales Commun Dis Rep CDR Rev 1997 7: R49-R54
Connolly M, Noah N, on behalf of the European Meningitis Surveillance Group . Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993–6 Epidemiol Infect 1999 122: 41–49
Ramsay M, Collins M, Rush M, Kaczmarski E . The epidemiology of meningococcal disease in England and Wales, 1996 and 1997 Eurosurveillance 1997 2: 74–76
Infectious diseases in Finland 1998 Annual report National Public Health Institute: Helsinki, Finland 1999
Gold R, Lepow ML, Goldschneider I et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants J Clin Invest 1975 56: 1536–1547
Gold R, Lepow ML, Goldschneider I et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children J Infect Dis 1979 140: 690–697
Peltola H, Safary A, Käyhty H et al. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-Acetyl-Negative and O-Acetyl-Positive group C polysaccharides Pediatrics 1985 76: 91–96
King WJ, MacDonald NE, Wells G et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children J Pediatr 1996 128: 196–202
Witherspoon RP, Lum LG, Storb R . Immunologic reconstitution after human marrow grafting Semin Hematol 1984 21: 2–10
Lum LG . The kinetics of immune reconstitution after human marrow transplantation Blood 1987 69: 369–380
Lum LG . Immune recovery after bone marrow transplantation Hematol Oncol Clin North Am 1990 4: 659–675
Storek J, Saxon A . Reconstitution of B cell immunity following bone marrow transplantation Bone Marrow Transplant 1992 9: 395–408
Winston DJ, Ho WG, Schiffman G et al. Pneumococcal vaccination of recipients of bone marrow transplants Arch Intern Med 1983 143: 1735–1737
Giebink GS, Warkentin PI, Ramsay NKC, Kersey JH . Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine J Infect Dis 1986 154: 590–596
Barra A, Cordonnier C, Preziosi M-P et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients J Infect Dis 1992 166: 1021–1028
Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K . Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation Clin Exp Immunol 1992 88: 512–519
Hammarström V, Pauksen K, Azinge J et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction Support Care Cancer 1993 1: 195–199
Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients Transplantation 1994 57: 677–684
Molrine DC, Guinan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation Blood 1996 87: 3012–3018
Parkkali T, Käyhty H, Ruutu T et al. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT Bone Marrow Transplant 1996 18: 961–967
Engelhard D, Cordonnier C, Shaw PJ et al. Invasive pneumococcal infection following PBSCT and BMT – an EBMT survey Bone Marrow Transplant 1999 23: (Suppl. 1) S114 (Abstr. 368)
Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 1994 84: 2036–2043
Tallman MS, Rowlings PA, Milone G et al. Role of postremission chemotherapy in recipients of HLA-identical sibling transplants for acute myelogenous leukemia in first remission Blood 1997 90: (Suppl. 1) 254a (Abstr. 1117)
Ruutu T, Volin L, Parkkali T et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study Blood 2000 96: 2391–2398
Heinonen H, Volin L, Uutela A et al. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation Ann Hematol (in press)
Platonov AE, Beloborodov VB, Pavlova LI et al. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine Clin Exp Immunol 1995 100: 32–39
Arakere G, Frasch CE . Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers Infect Immun 1991 59: 4349–4356
Holder PK, Maslanka SE, Pais LB et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992 Clin Diagn Lab Immunol 1995 2: 132–137
Peltola H, Mäkelä PH, Käyhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age New Engl J Med 1977 297: 686–691
Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1995 15: 455–460
Ljungman P . Immunization of transplant recipients Bone Marrow Transplant 1999 23: 635–636
Quinti I, Velardi A, Le Moli S et al. Antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation J Clin Immunol 1990 10: 160–166
Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment Blood 1981 58: 360–368
Käyhty H, Karanko V, Peltola H et al. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children J Infect Dis 1980 142: 861–868
Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial JAMA 1996 275: 1499–1503
MacDonald NE, Halperin SA, Law BJ et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial JAMA 1998 280: 1685–1689
Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory J Infect Dis 1999 179: 1569–1572
Brandt BL, Artenstein MS . Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide J Infect Dis 1975 131: (Suppl.) S69-S72
Zangwill KM, Stout RW, Carlone GM et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel J Infect Dis 1994 169: 847–852
Committee on Infectious Diseases, American Academy of Pediatrics Infectious Diseases and Immunization Committee, Canadian Paediatric Society . Meningococcal disease prevention and control strategies for practice-based physicians Pediatrics 1996 97: 404–411
Kalhs P, Panzer S, Kletter K et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease Ann Intern Med 1988 109: 461–464
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parkkali, T., Käyhty, H., Lehtonen, H. et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant 27, 79–84 (2001). https://doi.org/10.1038/sj.bmt.1702742
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702742
Keywords
This article is cited by
-
A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency
Infectious Diseases and Therapy (2021)
-
References
Bone Marrow Transplantation (2009)
-
Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT
Bone Marrow Transplantation (2005)